Dual Targets for Mouse Mast Cell Protease-4 in Mediating Tissue Damage in Experimental Bullous Pemphigoid by Lin, Lan et al.
Dual Targets for Mouse Mast Cell Protease-4 in Mediating
Tissue Damage in Experimental Bullous Pemphigoid*
Received for publication, June 15, 2011, and in revised form, August 22, 2011 Published, JBC Papers in Press, August 31, 2011, DOI 10.1074/jbc.M111.272401
Lan Lin‡§1,2, Eric Bankaitis§1,3, Lisa Heimbach§¶4, Ning Li§, Magnus Abrink, Gunnar Pejler**, Lijia An‡, Luis A. Diaz§,
Zena Werb‡‡, and Zhi Liu§¶5
From the ‡School of Life Science and Biotechnology, Dalian University of Technology, Dalian, 116024 Liaoning, China, the
Departments of §Dermatology and ¶Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina
27599-7290, the Departments of Biomedical Sciences and Veterinary Public Health and **Anatomy, Physiology, and Biochemistry,
Swedish University of Agricultural Sciences, 75123 Uppsala, Sweden, and the ‡‡Department of Anatomy, University of California,
San Francisco, California 94143-0452
Background: Experimental bullous pemphigoid is mediated by mast cells (MCs), which release proteases when activated.
Results: Mouse MC protease-4 (mMCP-4), the likely murine homolog of human MC chymase, activates the enzyme MMP-9
and directly injures the skin adhesion protein BP180.
Conclusion:MMCP-4 regulates experimental BP by two different mechanisms.
Significance:MMCP-4 is a potential therapeutic target for human BP treatment.
Mouse mast cell protease-4 (mMCP-4) has been linked to
autoimmune and inflammatory diseases, although the exact
mechanisms underlying its role in these pathological conditions
remain unclear. Here, we have found that mMCP-4 is critical in
a mouse model of the autoimmune skin blistering disease
bullous pemphigoid (BP). Mice lacking mMCP-4 were resistant
to experimental BP. Complement activation, mast cell (MC)
degranulation, and the early phase of neutrophil (PMN) recruit-
ment occurred comparably inmMCP-4/ andWTmice. How-
ever, without mMCP-4, activation of matrix metalloproteinase
(MMP)-9was impaired in culturedmMCP-4/ MCs and in the
skin of pathogenic IgG-injected mMCP-4/ mice. MMP-9
activation was not fully restored by local reconstitution with
WT or mMCP-4/ PMNs. Local reconstitution with mMCP-
4/ MCs, but not with mMCP-4/ MCs, restored blistering,
MMP-9 activation, and PMN recruitment inmMCP-4/ mice.
mMCP-4 also degraded the hemidesmosomal transmembrane
protein BP180 both in the skin and in vitro. These results dem-
onstrate thatmMCP-4plays twodifferent roles in the pathogen-
esis of experimental BP, by both activatingMMP-9 andby cleav-
ing BP180, leading to injury of the hemidesmosomes and
extracellular matrix of the basement membrane zone.
Mast cells (MCs)6 are key effector cells involved in innate and
adaptive immunity, as well as allergic and anaphylactic reac-
tions (1, 2). MCs are found in particularly high concentrations
in the connective tissues just below the epithelial surfaces of the
body, such as the submucosal tissues of the gastrointestinal and
respiratory tracts and the dermis of the skin, positioning them
as key sentinels against external challenges. Upon activation,
MCs degranulate and release preformed bioactive compounds
from their secretory granules, including histamine, cytokines,
proteoglycans, and proteases (3). Together, these inflammatory
mediators increase the permeability of local blood vessels and
recruit effector cells to the site. In addition to their role in pro-
tection against environmental stimuli, MCs are also implicated
in chronic inflammatory and autoimmune diseases. Mice lack-
ing MCs are partially or completely protected from disease in
animal models of multiple sclerosis, collagen-induced arthritis,
and bullous pemphigoid (BP) (4–6).
BP is an autoimmune skin blistering disease triggered by
autoantibodies against the hemidesmosomal transmembrane
protein BP180 (also called BPAG2 or type XVII collagen)
(7–13). Using an animalmodel of BP inwhich neonatal BALB/c
mice are injectedwith anti-murine BP180 (mBP180) antibodies
(14), we previously demonstrated that dermal-epidermal sepa-
ration is triggered by anti-BP180 IgG and depends on comple-
ment activation, MC degranulation, and neutrophil (PMN)
recruitment (15, 16). Activated PMNs release proteolytic
enzymes such as the serine proteinase neutrophil elastase (NE)
and gelatinase B/matrix metalloproteinase (MMP)-9, which in
turn degrade extracellular matrix (ECM) components of the
basement membrane zone (BMZ), leading to separation of the
dermis from the epidermis (17–19).
* This work was supported, in whole or in part, by National Institutes of Health
Grants AI40768 and AI61430 (to Z. L.), AR052109 and AR053313 (to N. L.),
AR32599 and AR32081 (to L. A. D.), and CA057621 (to Z. W.) from the
USPHS. This work was also supported by grants from the Swedish Medical
Research Council (to M. A. and G. P).
1 Both authors contributed equally to this work.
2 Supported in part by a predoctoral fellowship from the China Scholarship
Council.
3 Present address: Dept. of Cell and Developmental Biology, Vanderbilt Uni-
versity, Nashville, TN 37232-8240.
4 Supported in part by National Institutes of Health Predoctoral Fellowship
AI007273.
5 To whom correspondence should be addressed: Dept. of Dermatology, Uni-
versity of North Carolina, 116 Manning Dr., Rm. 422, Chapel Hill, NC 27599.
Tel.: 919-966-0788; Fax: 919-966-3898; E-mail: zhiliu@med.unc.edu.
6 The abbreviations used are: MC, mast cell; BMZ, basement membrane zone;
BP, bullous pemphigoid; ECM, extracellular matrix; mMCP, mouse mast cell
protease; MMP, matrix metalloproteinase; MPO, myeloperoxidase; NE,
neutrophil elastase, PMN, neutrophil; IF, immunofluorescence; i.d., intra-
dermal; 2-AP, 2-antiplasmin; uPA, urokinase-type plasminogen
activator.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 43, pp. 37358 –37367, October 28, 2011
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
37358 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 43 • OCTOBER 28, 2011
MC proteases are a major class of inflammatory mediators
stored in great quantities as fully active enzymes in the secre-
tory granules of MCs (20, 21). MC proteases are broken into
three classes as follows: chymases, tryptases, and carboxypepti-
dase A (22). In this study, we focus on one of several murine
chymases, mouse MC protease-4 (mMCP-4), which is widely
recognized as the likely homolog of the single identified human
chymase (23–25). Mice deficient in mMCP-4 (mMCP4/)
have normal numbers of MCs, no alteration in MC morphol-
ogy, and no abnormalities in the storage of otherMCproteases.
However,mMCP-4/mice exhibit a complete loss in chymot-
ryptic activity in ear tissue, indicating thatmMCP-4 is themain
source of stored chymotrypsin-like activity in the skin (25).
Using the mMCP-4/ mice, mMCP-4 activity has recently
been associated with inflammatory processes in allergic
asthma, immune complex-mediated glomerulonephritis, auto-
immune arthritis, and epidermal burn injury (26–29). Impor-
tantly, mMCP-4 can activateMMP-9 in vitro, a keymediator of
experimental BP (30). These observations, in conjunction with
the known role of MCs in BP, suggest that mMCP-4 may con-
tribute to the pathogenesis of BP. Using mMCP-4/ mice, we
demonstrate two pathogenic roles for mMCP-4 in experimen-
tal BP as follows: mMCP-4 contributes to activation of MMP-9
and also directly damages the ECM by degrading BP180.
EXPERIMENTAL PROCEDURES
Reagents—Purified murine MMP-9 was obtained from Tri-
ple Point Biologics, Inc. Purified PMNmyeloperoxidase (MPO)
was purchased from Athens Research and Technology, Inc.
(Athens, GA). Rabbit anti-mMCP-4 antibody was made
in-house as described previously (31). mMCP-4 was purified as
described previously (32). Protein concentration was deter-
mined with the RC DC protein assay purchased from Bio-Rad.
The ECLWestern blotting analysis kit was purchased from GE
Healthcare.
Laboratory Animals—C57BL/6J mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). mMCP4/ mice
were generated and backcrossed onto B6 background as
described previously (25). The mice were maintained at the
University of North Carolina Chapel Hill Animal Center. Neo-
natal mice (24–36 h old with body weights between 1.4 and
1.6 g) were used for passive transfer experiments, and adult
mice (8–10 weeks old) were used for mast cell reconstitution
experiments. Animal care and animal experiments were
approved by the Animal Care Committee at the University of
North Carolina, Chapel Hill.
Preparation of Pathogenic Anti-BP180 IgG—The preparation
of recombinant murine BP180ABC and the immunization of
rabbits were performed as described previously (14). Briefly, a
segment of the ectodomain of the murine BP180 antigen (33)
was expressed as a glutathione S-transferase (GST) fusion pro-
tein using the pGEX prokaryotic expression system (GE
Healthcare). The murine BP180 fusion protein, designated
GST-mBP180ABC containing NC14A and half of C13
domains, was purified to homogeneity by affinity chromatogra-
phy using a glutathione-agarose column (34). New Zealand
White rabbits were immunized with purified GST-
mBP180ABC, and the IgG fraction from the serum (designated
R530) was purified as described previously (14). The IgG frac-
tions were concentrated and sterilized by ultrafiltration, and
the protein concentrations were determined by A280 (E (1%, 1
cm) 13.6). The titers of anti-murine BP180 antibodies in both
the unfractionated rabbit serumand in the purified IgG fraction
were assayed by indirect immunofluorescence (IF) usingmouse
skin cryosections as substrate. The antibody preparations were
also tested by immunoblotting against the GST-mBP180ABC
fusion protein. The IF and immunoblotting techniques have
been reported elsewhere (14). The pathogenicity of these IgG
preparations was tested by passive transfer experiments as
described below.
Induction of Experimental BP and Clinical Evaluation of
Animals—Neonates were given on the back one intradermal
injection of a sterile solution of IgG in PBS (50 l of IgG, 2.64
mg of IgG/g body weight) as described previously (14). The
extent of cutaneous disease was scored as follows: 0, no detect-
able skin disease; 1, mild erythematous reaction with no evi-
dence of the epidermal detachment sign (elicited by gentle fric-
tion of the mouse skin; when positive, this produced fine,
persistent wrinkling of the epidermis); 2, intense erythema and
epidermal detachment sign involving 10–50% of the epidermis
in localized areas; 3, intense erythema with frank epidermal
detachment sign involving more than 50% of the epidermis in
the injection site. After clinical examination, the animals were
sacrificed, and skin and serum specimens were obtained. Each
skin section (6 6mm in size) was analyzed byH&E staining
and routine histological examination to localize the lesional site
and PMN infiltration, by direct IF assays to detect rabbit IgG
and mouse C3 deposition at the BMZ, and by MPO enzymatic
assay to quantify the PMN accumulation at the skin injection
site as described below. Direct and indirect IF studies were per-
formed as described previously (14) using commercially avail-
able FITC-conjugated goat anti-rabbit IgG (Kirkegaard& Perry
Laboratories Inc.). Monospecific goat anti-mC3 IgG was pur-
chased from Cappel Laboratories.
Quantification of MCs and MC Degranulation—Skin sec-
tions (3  3 mm) of IgG-injected mice were fixed in 10%
formalin. Paraffin sections (6 m thick) were prepared and
stained with toluidine blue and H&E staining. Dermal MCs
were counted by two individuals in the laboratory in a blinded
fashion and classified as degranulated (10% of the granules
exhibiting fusion or discharge) or normal in five random fields
under a light microscope at 400 magnification (4, 35). MCs
with complete degranulation that may be missed by toluidine
blue staining were identified by indirect IF with FITC-conju-
gated rat anti-mouse c-Kit monoclonal antibody (BD Biosci-
ences). Results were expressed as percentage of degranulated
MC (number of degranulatingMCs per total number ofMCs in
five random fields  100%).
Quantification of PMN Accumulation at Antibody Injection
Sites—Tissue MPO activity was used as an indicator of PMNs
within skin samples of experimental animals as described else-
where (36).We previously showed that clinical skin blistering is
directly correlated with the number of infiltrating PMNs in the
IgG injection site (16). The mouse skin samples (3  6 mm)
were extracted by homogenization in 500 l of extraction
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MC Reconstitution—mMCP-4/ mice were reconstituted
selectively and locally by the injection of growth factor-depen-
dent bone marrow-derived cultured MCs into the skin (4, 37,
38). Briefly, femoral bone marrow cells from WT and mMCP-
4/ mice were maintained in vitro for 4 weeks in RPMI 1640
completemedium (Invitrogen) supplementedwith 20%WEHI-
3-conditioned medium until MCs represented 95% of the
total cells as determined by toluidine blue staining and flow
cytometry analysis using antibodies specific for the MC cell
surface markers FcRI, c-Kit, and CD13 (37). Murine IgE and
rat anti-mouse IgE were purchased from Southern Biotechnol-
ogyAssociates (Birmingham,AL). FITC-labeled rat anti-mouse
c-Kit and FITC-labeled rat anti-mouse CD13 were obtained
fromDBPharmingen (SanDiego, CA).MCs (1 106 in 20l of
medium) were injected i.d. into the ears of 8–10-week-old
MCP-4/ mice. Medium alone (20 l) was injected i.d. into
the ears ofmMCP-4/mice to serve as negative controls. This
procedure selectively and locally reconstitutes the dermal MC
population without systemic effects (38). MC reconstitution
was confirmed by staining skin sections fromMC-injected sites
with toluidine blue. Ten weeks after the adoptive transfer of
MCs, when the injected MCs were fully matured into func-
tional cutaneous MCs (4, 37, 38), both ears of the mice were
injected i.d. with pathogenic anti-BP180 IgG (2 mg/20 l/site).
24 h later, ear skin biopsies were obtained and analyzed byH&E
staining, toluidine blue staining, and MPO enzyme assay as
described above.
Isolation of PMNs and Local PMN Reconstitution—PMNs
were isolated from heparinized blood from WT and mMCP-
4/ mice by dextran sedimentation followed by separation on
a density gradient (39). PMN purity of the final cell preparation
was consistently greater than 96% as determined by cell cytos-
pin and LeukoStat staining (FisherDiagnostics). The viability of
the PMNs was greater than 96% as determined by trypan blue
exclusion. PMNs were kept in PBS with 10 mM glucose at 4 °C
before use. For PMN reconstitution, neonatal mice were
injected i.d. with pathogenic IgG and, 90 min later, 5  105
purifiedmouse PMNs in 50l of PBSwere injected into the IgG
injection site.
Activation of Pro-MMP-9 in Mast Cell Culture—Bone mar-
row-derived cultured MCs (1  106 MCs/ml) were stimulated
with recombinant mouse C5a (50 ng/ml) at 37 °C for 1 h. Cells
were centrifuged at 14,000 rpm at 4 °C for 10 min. The super-
natant was incubated with purified mouse pro-MMP-9 (1
g/ml) at 37 °C for 4 h in the absence or presence of rabbit
anti-mMCP-4 antibody. The digestion mixtures were analyzed
by gelatin zymography as described below.
Gelatin Zymography—Gelatinase profiles were determined
by zymography as described previously (40). In brief, protein
extracts of skin sections from injected animals were subjected
to SDS-PAGE on gelatin-containing acrylamide gels (10%
acrylamide and 1% gelatin) under nonreducing conditions.
After electrophoresis, gels were washed twice with 2.5% Triton
X-100 for 30 min to remove SDS. Gels were then rinsed briefly
with water followed by incubation overnight at 37 °C in reac-
tion buffer containing 50 mM Tris, pH 7.4, 150 mMNaCl, and 5
mM CaCl2. The gels were stained with 0.125% Coomassie Bril-
liant Blue. Areas of gelatinolytic activity appeared as clear zones
against a dark blue background.
Colorimetric Assay—Levels ofMMP-9 weremeasured with a
MMP colorimetric assay kit following manufacturer’s instruc-
tions (BIOMOL Research Laboratories, Plymouth Meeting,
PA) with minor modifications (41). Briefly, supernatant sam-
ples were incubated with the MMP colorimetric substrate or
treated with -amino-3-hydroxy-5-methyl-4-isoxazolepropi-
onic acid to activateMMP-9 and then incubatedwith theMMP
colorimetric substrate Ac-PLG[2-mercapto-4-methyl]-LG-
OC2H5 in reaction buffer (final substrate concentration  100
M) at 37 °C.MMP activity in protein extracts wasmeasured by
the change in absorbance at 412 nm and was expressed as rela-
tive MMP activity (A412 nm reading/min/mg of protein of
mouse skin injected with pathogenic IgG  A412 nm reading/
min/mg protein of mouse skin injected with normal control
IgG).
Injection of 2-AP Plasmin Inhibitor—Neonatal mice were
injected i.d. with 50 l of human 2-AP (25 g/g body weight)
prior to injection of pathogenic IgG (2.64 mg/g body weight) as
described previously (42). Endotoxin levels in 2-AP prepara-
tions were minimal; mice injected with 2-AP showed no
inflammatory response in the skin as determined by MPO
enzyme activity assay.
Dermal-Epidermal Separation bymMCP-4 in Vitro—Mouse
skin sections were obtained from neonatal BALB/c mice
(36–48 h old) and cut into 2  2-mm strips with a razor blade.
The skin strips were then incubated in minimum essential
medium either with or without 1 g/ml mMCP-4 at 37 °C for
various periods of time. At the end of the incubation, the skin
strips were rinsed in freshminimum essential medium, fixed in
10% formalin, and embedded in paraffin, sectioned and stained
with H&E. To identify BP180 degradation, mouse skin sections
were homogenized in Tris-EDTA buffer containing 2% SDS,
0.5% Nonidet P-40, pH 6.8, plus proteinase inhibitors. Protein
extracts were analyzed for BP180 degradation by SDS-PAGE
(7%) followed by immunoblotting (19), using rabbit anti-
mBP180 IgG andmonospecific FITC-conjugated goat anti-rab-
bit IgG (Kirkegaard & Perry Laboratories Inc., Gaithersburg,
MD).
mMCP-4 Digestion of Recombinant mBP180—TheGST por-
tion of the GST-mBP180ABC fusion protein described above
was removed by PreScission protease cleavage, followed by
purification on a glutathione column. Purified mBP180ABC
protein (2 g) was incubated with mMCP-4 or purified human
chymase (1.25 milliunits) in PBS. Reactions were carried out at
37 °C for 0–60 min and terminated by adding an equal volume
of SDS-PAGE sample buffer and heating at 100 °C for 5 min.
Reaction mixtures were then resolved by electrophoresis
through 18% SDS-polyacrylamide gels. The mBP180ABC and
its degraded fragments were detected by immunoblotting using
rabbit anti-mBP180 IgG.
Statistical Analysis—For statistical analysis, the data were
expressed as mean  S.E. and were analyzed using the Exact
Wilcoxon Two-sample Test or Student’s t test. A p value less
than 0.05 was considered significant.
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RESULTS
mMCP-4-deficient Mice Are Resistant to Experimental BP—
To determine whether mMCP-4 is critical for the formation of
subepidermal blisters in experimental BP, neonatal C57BL/6J
(WT) and mMCP-4-deficient (mMCP-4/) mice were
injected with pathogenic anti-mBP180 IgG (2.64 mg/g body
weight) and assessed for disease susceptibility. 24 h after injec-
tion, WT mice developed clinical blisters (Fig. 1A), although
mMCP-4/ mice were resistant to disease (Fig. 1E). By direct
IF, the perilesional skin of both WT and mMCP-4/ mice
exhibited deposition of rabbit IgG (Fig. 1, B and F) and murine
complement components (Fig. 1, C and G) along the dermal-
epidermal junction, indicating that the lack ofmMCP-4 did not
affect antibody deposition or complement activation. H&E-
stained skin sections confirmed that mMCP-4/ mice had no
loss of dermal-epidermal adhesion, whereas WT mice devel-
oped subepidermal separation (Fig. 1, D and H). Skin disease
severity inmMCP-4/micewas significantly reduced as com-
pared with WT mice (Fig. 1I).
PMNRecruitment, butNotMCDegranulation, Is Impaired in
mMCP-4-deficient Mice—Having determined that comple-
ment deposition is unaffected by the absence of mMCP-4, we
next investigated MC degranulation and PMN recruitment,
which occur downstream of complement activation in BP
pathogenesis (4, 43). 2 h after injection with pathogenic IgG,
toluidine blue staining revealed extensive MC degranulation in
the dermis of bothWT andmMCP-4/ mice (Fig. 2,A and B).
Quantification ofMCdegranulation revealed no significant dif-
ference between WT and mMCP-4/ animals injected with
pathogenic antibody (Fig. 2C). Thus, MC degranulation is not
impaired by the absence of mMCP-4.
Quantification of MPO activity demonstrated that 4 h post-
injection,WT andmMCP-4/mice recruit comparable num-
bers of PMNs to the skin (Fig. 2D, bars 1 and 2). However, 12
and 24 h post-injection, themMCP-4/mice exhibited signif-
icantly lower levels of PMN recruitment than WT mice (Fig.
2D, bars 3–6). These data indicate that mMCP-4 is not
required for the initial phase of MC-mediated PMN recruit-
ment, but it is critical for the secondary amplification phase of
PMN accumulation.
mMCP-4 Activates MMP-9—mMCP-4 can process pro-
MMP-9 to its active form in vitro (30), andMMP-9 is critical for
experimental BP (17, 18). Therefore, we tested whether
mMCP-4 is involved in activation of MMP-9 in experimental
BP. We detected the levels of pro-MMP-9 and active MMP-9
present in the skin of WT and mMCP-4/ mice at 4 and 24 h
post-antibody injection. Both the pro- and active forms of
MMP-9 were seen in lesional and nonlesional skin samples of
pathogenic IgG-injectedWT and mMCP-4/ mice by gelatin
zymography after 4 and 24 h (Fig. 3A, lanes 1–4), although
MMP-9 band densities inmMCP-4/micewere oftenweaker
than those in WT mice. No active MMP-9 was seen in skin
samples of control IgG-injected mice (Fig. 3A, lanes 5 and 6).
We used a highly sensitive MMP colorimetric assay to quantify
the levels of active MMP-9 in the skin ofWT andmMCP-4/
animals at 0, 4, 12, and 24 h after antibody injection. In keeping
with the PMN recruitment results, we observed that, although
there was no difference in the levels of active MMP-9 between
mMCP-4/ and WT animals at 4 h post-injection, there was
significantly less active MMP-9 in the skin of pathogenic IgG-
injected mMCP-4/ mice at 12 and 24 h as compared with
MMP-9 levels in the lesional skin of the diseased WT mice 12
and 24 h post-injection (Fig. 3B). MMP-9/ mice exhibit only
background levels of MMP activity up to 24 h after pathogenic
antibody injection using this colorimetric assay (data not
shown and see Ref. 42).
To further establish that mMCP-4 released from MCs acti-
vates pro-MMP-9, we degranulated cultured bone marrow-de-
rived mouse MCs from WT and mMCP-4/ mice with
recombinant C5a (rC5a) and collected the supernatant. Upon
incubation with the rC5a-activated WT supernatant for 4 h at
37 °C, recombinant pro-MMP9 was converted into active
MMP-9 (Fig. 3C, lane 1). Activation was completely blocked by
addition of rabbit anti-mMCP-4 antibody to the supernatant
(Fig. 3C, lane 3). Supernatants from cultured WTMCs treated
with BSA instead of rC5a were unable to convert pro-MMP-9
to the active form (Fig. 3C, lane 2). Supernatants from cultured
mMCP-4/ MCs treated with rC5a also failed to activate
MMP-9 (Fig. 3C, lane 4). Taken together, the in vitro and in vivo
data strongly suggest that mMCP-4 released from degranulat-
ing MCs activates MMP-9.
PMN Reconstitution Restores Skin Blistering but Not MMP-9
Activation in mMCP-4/ Mice—Infiltrating PMNs are a
major source of MMP-9 in experimental BP (18). mMCP-4/
mice fail to recruit the secondary wave of PMNs to the skin,
which likely contributes to the reduction in active MMP-9
observed 12 and 24 h after pathogenic antibody injection. To
determine the relative contributions of reduced PMN recruit-
ment and mMCP-4 deficiency to the lower levels of active
MMP-9 observed in mMCP-4/ mice, we locally reconsti-
tuted mMCP-4/ mice with PMNs to restore PMN levels.
mMCP-4/ mice injected with pathogenic antibodies alone
were resistant to experimental BP (Fig. 4B). However, mMCP-
4/ mice locally injected with 5  105 WT or mMCP-4/
PMNs 2 h after pathogenic antibody injection developed skin
blisters (Fig. 4, C and D) equivalent to WT mice injected with
pathogenic antibodies alone (Fig. 4A).
Four hours post-injection, WT and mMCP-4/ mice given
pathogenic antibodies alone recruited equivalent numbers of
PMNs to the skin and exhibited comparable levels of MMP-9
activity (Fig. 4, E, bars 5 and 6, and F, bars 5 and 6; also see Figs.
2D and 3B). MPO analysis confirmed that within 2 h of PMN
injection (4 h post-IgG injection), the PMN-reconstitutedmice
exhibited significantly higher levels of skin PMNs than theWT
and mMCP-4/ mice injected with antibody alone (Fig. 4E,
bars 7 and 8 versus bars 5 and 6). However, MMP-9 activity is
not significantly different between the four groups of mice (Fig.
4F, bars 5–8). These data suggest thatMMP-9 activation at the
early stage of disease is not dependent on either PMNs or
mMCP-4.
24 h post-injection, skin PMN levels were not significantly
different between the PMN-reconstituted mMCP-4/ mice
and the WT mice injected with pathogenic antibodies alone
(Fig. 4E, bars 11 and 12 versus bar 9). However,MMP-9 activity
was significantly lower in the reconstituted mMCP-4/ mice
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than the WTmice (Fig. 4F, bars 11 and 12 versus bar 9). These
data demonstrate that artificial recruitment of PMNs to the
skin in the mMCP-4/ animals does not completely restore
MMP-9 activity toWT levels, indicating that differences in the
numbers of skin PMNs alone cannot account for the difference
in MMP-9 activation observed.
FIGURE 1. mMCP-4-deficient mice are resistant to experimental BP. Neo-
natal WT and mMCP-4-deficient (mMCP4/) mice were injected i.d. with
pathogenic rabbit anti-mBP180 IgG (2.64 mg/g body weight) and examined
24 h post-injection. A, WT mice develop clinical blisters. Direct IF showed
deposition of rabbit IgG (B) and mouse C3 (C) at the BMZ. H&E staining
revealed dermal-epidermal separation (D). mMCP-4/ mice receiving the
same dose of pathogenic IgG showed no skin lesions clinically (E) and histo-
logically (H), although BMZ deposition of IgG (F) and C3 (G) were seen in the
skin. e, epidermis; d, dermis. Arrow, basal keratinocytes. 100 magnification.
I, clinical examination of the IgG-injected mice showed a drastic reduction of
skin disease severity (expressed as mean  S.E.) in mMCP-4/ mice as com-
pared with WT control. Eight mice per group. *, p  0.001 (bar 3 versus 4). The
Exact Wilcoxon Two-sample Test was used. SE, standard error; Min, minimum;
Max, maximum.
FIGURE 2. mMCP-4 deficiency does not impair mast cell degranulation.
Neonatal WT and mMCP4/ mice were injected i.d. with pathogenic rabbit
anti-mBP180 IgG (2.64 mg/g body weight) and examined at different time
points post-injection. A and B, toluidine blue staining showed similar degrees
of mast cell (MC) degranulation in pathogenic IgG-injected WT and mMCP-
4/ mice at 2 h post-injection, when MC degranulation reaches the peak
level. Arrow, degranulating mast cells. C, quantification of MC degranulation
(expressed as % of MC degranulation) further confirmed that there was no
difference in the number of degranulating MCs in the dermis of IgG-injected
WT and mMCP-4/ mice. D, quantification of infiltrating PMNs in the skin by
measuring MPO activity (expressed as relative MPO activity, A460 nm/mg of
protein) showed similar levels of PMN recruitment at 4 h, but significantly
reduced levels at 12 and 24 h between the two groups of mice. n  6 for each
group. *, p  0.01.
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mMCP-4 Directly Degrades BP180—Our data thus far indi-
cate that mMCP-4 mediates inflammatory destruction of the
ECM indirectly by regulating the activity of MMP-9. However,
many MC proteases are also capable of directly cleaving ECM
components (21). To determine whether mMCP-4 is able to
directly cause tissue damage,we incubatedneonatalmouse skin
sections with 1 g/ml mMCP-4 or medium alone for 12 h at
37 °C.When examined byH&E staining, the sections incubated
with mMCP-4, but not medium alone, exhibited dermal-epi-
dermal separation (Fig. 5A). We extracted proteins from the
sections and immunoblotted for BP180. A single strong 180-
kDa band corresponding to intact BP180 was detected in the
medium-incubated sections, although both intact and cleaved
BP180 bands were detected in the lysates frommMCP-4-incu-
bated sections (Fig. 5B). These data show thatmMCP-4 is capa-
ble of cleaving BP180 in tissue directly and causing dermal-
epidermal separation.
To confirm that mMCP-4 directly degrades BP180, we per-
formed an in vitro degradation assay by incubating purified
mMCP-4 with purified recombinant protein (mBP180ABC) as
the substrate. mBP180ABC corresponds to a 20-kDa portion of
FIGURE 3. MMP-9 activation by mMCP-4 in vivo and in vitro. A, neonatal WT
and mMCP-4/ mice were injected i.d. with control IgG or pathogenic anti-
mBP180 IgG. Skin samples were obtained at 4 and 24 h after IgG injection, and
protein extracts (30 g/lane) were analyzed by gelatin zymography. Both the
pro- and active forms of MMP-9 were seen in skin samples of pathogenic
IgG-injected WT (lanes 3 and 4) and mMCP-4/ mice (lanes 1 and 2) at both
time points. B, MMP colorimetric assay revealed a significant reduction of
active MMP-9 in the skin samples of pathogenic IgG-injected mMCP-4/
mice at 12 and 24 h as compared with active MMP-9 levels in the lesional skin
of diseased WT mice (bars 6 and 8 versus 5 and 7). At 4 h, WT and mMCP-4/
mice showed compatible levels of active MMP-9 (bars 3 and 4). MMP-9/
mice exhibit background levels of activity at 0, 4, 12, and 24 h after injection
with pathogenic antibodies (not shown). *, p  0.01. n  6 for each group. C,
bone marrow-derived MCs (1  106) from WT or mMCP-4/ mice were stim-
ulated with recombinant C5a (50 ng/ml) at 37 °C for 1 h. The supernatants
were then incubated with recombinant pro-MMP-9 (1 g/ml) at 37 °C for 4 h.
The digestion mixtures were analyzed by gelatin zymography. The superna-
tant of C5a-treated (lane 1) and not BSA control-treated (lane 2) MCs activated
pro-MMP-9. Addition of rabbit anti-mMCP-4 antibody to the C5a-treated
supernatant completely blocked MMP-9 activation (lane 3). C5a-activated
mMCP-4/ MC supernatants do not activate MMP-9 (lane 4).
FIGURE 4. Local PMN reconstitution restores levels of skin PMNs and skin
disease but not levels of active MMP-9. Neonatal WT and mMCP-4/ mice
were injected i.d. with pathogenic antibodies and 2 h later locally reconsti-
tuted with 5  105 PMNs from WT or mMCP-4/ mice. WT mice injected with
pathogenic IgG (A) and mMCP-4/ mice reconstituted with WT PMNs (C) or
mMCP-4/ PMNs (D) developed BP blisters. Unreconstituted mMCP-4/
mice do not develop skin blisters (B). E, MPO activity assay of mouse skin
samples revealed that at 4 h the PMN-reconstituted mMCP-4/ mice (bars 7
and 8) had significantly increased number of PMNs compared with WT mice
(bar 5). At 24 h, PMN-reconstituted mMCP-4/ mice (bars 11 and 12) exhib-
ited higher but not statistically significant numbers of PMNs as compared
with WT (bar 9). F, MMP-9 activity assay revealed compatible levels of active
MMP-9 at 4 h (bars 7 and 8 versus 5) and reduced levels of active MMP-9 at 24 h
(bars 11 and 12 versus 9) between PMN-reconstituted mMCP-4/ and WT
mice. *, p  0.05. n  6 for each group.
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the murine BP180 extracellular domain. Degradation products
ofmBP180ABCare detectable by immunoblottingwithin 5min
of incubation with mMCP-4 (Fig. 5C).
MC Reconstitution Restores BP in mMCP-4-deficient Mice—
We next performed a series of MC reconstitution experiments
to confirm that mMCP-4 released fromMCs is crucial for der-
mal-epidermal separation, activation of MMP-9, and PMN
recruitment. We injected the left ears of mMCP-4/ mice
withmMCP-4/MCs and the right ears of the samemicewith
mMCP-4/ MCs (1  106 cells/site). mMCP-4/ mice were
injected with PBS as controls. Ten weeks later, both ears of the
mice were injected i.d. with pathogenic anti-BP180 IgG (2
mg/20-l/site) and examined 24 h post-IgG injection. We
observed similar numbers of MCs in the mMCP-4/ MC-re-
constituted ears and the mMCP-4/ MC-reconstituted ears.
PBS-injected mMCP-4/ controls and mMCP-4/ mice
reconstitutedwithmMCP-4/MCswere protected fromblis-
tering, althoughmMCP-4/ mice reconstituted withmMCP-
4/ mast cells developed dermal-epidermal separation (Fig. 6,
A–C). The mMCP-4/ ears reconstituted with mMCP-4/
MCs exhibited significantly higher levels of active MMP-9 and
PMN infiltration than themMCP-4/ ears reconstituted with
mMCP-4/ MCs (Fig. 6, F, bars 3 and 4, and G, bars 3 and 4).
WT mice injected with pathogenic antibody developed der-
mal-epidermal separation as expected, and this blistering was
completely blocked by pretreatment with an anti-mMCP-4
antibody (Fig. 6,D and E). Pretreatment with the anti-mMCP-4
FIGURE 5. mMCP-4 produces dermal-epidermal separation of the skin
and cleaves BP180 in tissue and in vitro. A, neonatal mouse skin sections
were incubated with culture medium alone or with mMCP-4 (1 g/ml) at
37 °C for 12 h and were examined by H&E staining. Dermal-epidermal sepa-
ration was seen in the skin incubated with mMCP-4 (right panel) but not the
medium control (left panel). E, epidermis; D, dermis. Arrow, basal keratino-
cytes. 100 magnification. B, protein extracts from mouse skin incubated
with culture medium alone or mMCP-4 above were analyzed by immunoblot-
ting using an anti-mBP180 antibody. mMCP-4 (lane 2), but not culture
medium (lane 1), degraded BP180. C, recombinant mBP180ABC was incu-
bated with mMCP-4 at 37 °C for 0 – 60 min. The digestion products were
resolved by SDS-PAGE and detected by immunoblotting using an anti-
mBP180 antibody. Degradation products were seen after incubation with
mMCP-4 for 5, 15, 30, and 60 min. FIGURE 6. MC reconstitution restores BP in mMCP-4-deficient mice. Path-
ogenic antibodies were injected into ears of WT mice, WT mice pretreated
with anti-mMCP-4 antibody, mMCP-4/ mice, and mMCP-4/ mice recon-
stituted with 1  106 MCs from either mMCP-4/ mice or WT mice. The ears
were examined 24 h post-IgG injection. H&E staining showed that WT mice
(D) and mMCP-4/ mice reconstituted with WT MCs (C) developed dermal-
epidermal junction separation following antibody injection. mMCP-4/
mice reconstituted with PBS (A) or reconstituted with mMCP-4/ MCs (B)
failed to develop dermal-epidermal junction separation. Pretreatment with
anti-mMCP-4 antibody abolished pathogenic IgG-induced skin lesions in WT
mice (E). F, quantification of active MMP-9. MMP colorimetric assay revealed
that lesional skin of WT MC-reconstituted mMCP-4/ mice (bar 4) had signif-
icantly elevated levels of active MMP-9 compared with mMCP-4/ mice
reconstituted with mMCP-4/ MCs (bar 3). Anti-mMCP-4 antibody treat-
ment led to a significant decrease in active MMP-9 levels in WT mice (bar 7) as
compared with WT mice without mMCP-4 blocking (bar 6). G, quantification
of PMN infiltration. Pathogenic antibodies induced experimental BP with sig-
nificantly increased PMN infiltration in WT mice (bar 6) and mMCP-4/ mice
reconstituted with WT MCs (bar 4) but not mMCP-4/ mice reconstituted
with mMCP-4/ MCs (bar 3) and WT mice pretreated with anti-mMCP-4 anti-
body (bar 7). *, p  0.01, six mice per group. Three independent experiments
were done for each group of mice.
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antibody also significantly reduced the levels of active MMP-9
and PMN infiltration in the ears (Fig. 6, F, bar 6 versus 7, andG,
bar 6 versus 7). Taken together, these data show that mMCP-4
released from MCs is critical for the activation of MMP-9, the
secondary wave of PMN infiltration, and blister formation.
mMCP-4 and Plasmin Are Required for MMP-9 Activation
and Skin Blistering—We previously showed that plasmin plays
a critical role in the early stages of experimental BP by activat-
ingMMP-9 (42). In light of our data implicatingmMCP-4 as an
important mediator of MMP-9 activation, we next sought to
clarify the relationship of plasmin and MMCP-4 in MMP-9
activation. We treated mMCP-4/ mice with the plasmin
inhibitor2-antiplasmin (2-AP) and injected the animalswith
pathogenic antibody. At 4, 24, and 48 h after antibody injection,
the 2-AP-treated mMCP-4/ mice had greater levels of
PMN infiltration and activatedMMP-9 than at time 0 (Fig. 7,A
and B), indicating that MMP-9 is activated in the absence of
both mMCP-4 and the plasmin cascade. Both MPO and
MMP-9 activity were significantly lower in the 2-AP-treated
mMCP-4 mice than inWT or untreated mMCP-4 mice 24 and
48 h post-injection (Fig. 7, A and B, bars 7 and 8 versus 9).
Untreated mMCP-4/ and 2-AP treated mMCP-4/ mice
are both protected from disease 24 h after pathogenic antibody
injection (Fig. 7C, bars 2 and 3). 48 h after injection, themMCP-
4/ and mMCP-4/ mice treated with 2-AP exhibited
modest increases in disease score but were still significantly
protected from blistering as compared with WT animals (Fig.
7C, bars 5 and 6 versus 4). These data indicate that both
mMCP-4 and plasmin play major roles in MMP-9 activation
and skin blistering and that additional pathway(s) of MMP-9
activation exist in experimental BP.
DISCUSSION
The role of MC proteases in autoimmune and inflammatory
diseases is currently a very active area of research.mMCP-4 has
garnered particular interest in recent years because of its
homology with humanMC chymase and the recent generation
of an mMCP-4-deficient line of mice (23–25). In this study, we
provide the first evidence for the mechanisms by which
mMCP-4 mediates an autoimmune disease. In experimental
BP, mMCP-4 has two key functions. 1) It activates MMP-9 and
indirectly drives the second phase of PMN infiltration, a critical
step required to amplify disease activity for clinical skin blister-
ing. 2) It directly cleaves the autoantigen BP180, a key compo-
nent of the ECM.
We previously elucidated critical roles for NE andMMP-9 in
experimental BP (17–19). These enzymes are released from the
first wave of PMNs recruited to the inflamed skin by degranu-
lated MCs (4 h post-injection). MMP-9 inactivates the serpin
1-proteinase inhibitor, the principal plasma inhibitor of NE
(44). When relieved of 1-proteinase inhibitor inhibition, NE
degrades components of the extracellular matrix, including
BP180, leading to dermal-epidermal separation and a second-
FIGURE 7. Both mMCP-4 and plasmin are required for MMP-9 activation
and BP blistering. WT and mMCP-4/ mice were pretreated with buffer
control or plasmin inhibitor 2-AP and 2 h later were injected i.d. with path-
ogenic antibodies. The mice were examined at 0, 4, 24, and 48 h. A, quantifi-
cation of PMN infiltration. MPO assay showed that at 4 h, compatible levels of
PMN infiltration were seen in IgG-injected WT (bar 4) and mMCP-4/ (bar 5)
and 2-AP-treated mMCP-4/ mice (bar 6). At 24 h, both mMCP-4/ (bar 8)
and 2-AP-treated mMCP-4/ mice (bar 9) showed significantly reduced
PMN infiltration as compared with WT mice (bar 7). PMN numbers in 2-AP-
treated mMCP-4/ mice were also significantly lower than mMCP-4/
mice. At 48 h, 2-AP-treated mMCP-4/ (bar 12) but not mMCP-4/ mice
(bar 11) showed significantly reduced PMN infiltration as compared with WT
mice (bar 10). B, quantification of active MMP-9. MMP colorimetric assay
revealed that at 4 h, compatible levels of active MMP-9 were present in IgG-
injected WT (bar 4) and mMCP-4/ (bar 5) and 2-AP-treated mMCP-4/
mice (bar 6). At 24 and 48 h, both mMCP-4/ (bars 8 and 11) and 2-AP-
treated mMCP-4/ mice (bars 9 and 12) showed significantly reduced active
MMP-9 levels as compared with WT mice (bars 7 and 10). At 48 h, 2-AP-
treated mMCP-4/ mice (bar 12) also showed significantly reduced levels of
active MMP-9 as compared with mMCP-4/ mice (bar 11). C, clinical disease
activity. WT mice (bars 1 and 4) developed extensive skin blisters, although
mMCP-4/ and 2-AP-treated mMCP-4/ mice showed no skin blistering
at 24 h (bars 2 and 3) and drastically reduced skin lesions at 48 h (bars 5 and 6).
*, p  0.01, 6 mice per group. The Exact Wilcoxon Two-sample Test was used.
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ary wave (amplification) of PMN infiltration. Our study shows
that BP180 is also a substrate for mMCP-4. mMCP-4 cleaves
BP180 both in vitro and in vivo. Whether mMCP-4 degrades
other critical hemidesmosomal and extracellular matrix pro-
teins and whether mMCP-4 and NE act independently or in
concert in experimental BP are currently under investigation in
our laboratory.
Extracellular proteolysis is critical for development, tissue
repair, and progression of diseases in vivo (45). The processes of
activating the zymogen forms of proteinases are strictly regu-
lated and locally confined to prevent unwanted cascades of pro-
teinase activation. MMP-9 is stored in inflammatory cells as a
zymogen and is activated extracellularly. Our present results
show that mMCP-4 secreted by degranulated MCs activates
MMP-9 in experimental BP.mMCP-4 is produced only byMCs
(46, 47), andWTMC reconstitution restores the blister pheno-
type in mMCP-4/ mice (Fig. 6).
Pro-MMP-9 also can be activated by plasmin, uPA (48–52),
chymase (53), tissue kallikrein (54), and other active MMPs
(55–59). We previously demonstrated that MMP-9 is activated
by plasmin or an indirect plasmin-dependent pathway and not
by uPA, tissue plasminogen activator, and MMP-3 during the
early stages of experimental BP disease development (42). Mice
lacking plasmin activity (because of a lack of plasminogen or
both tissue plasminogen activator and uPA) showminimal lev-
els ofMMP-9 activation and no skin lesions at 12 h post-patho-
genic IgG injection. At a later time point (24 h), however, path-
ogenic IgG induces subepidermal blisters in these knock-out
mice (34). In contrast, mMCP-4/ mice are resistant to BP at
both early (12 h) and late (24 h) stages of the disease process.
These findings suggest that plasmin activatesMMP-9mainly at
the early stage of the disease development, although mMCP-4
activates MMP-9 in the later stage of disease progression. It is
not yet clear how these pathways of MMP-9 activation overlap
or synergize. Our data demonstrating that mMCP-4/ mice
do not develop clinical or histological blistering indicate that
plasmin alone is not sufficient to activate MMP-9 and induce
disease. Mice lacking either mMCP-4 or plasmin activity are
protected from disease, indicating that both of these pathways
play a critical role in disease development. Interestingly, we
demonstrated that mice lacking both mMCP-4 and plasmin
activity still exhibit modest MMP-9 activation and develop
mild disease over 48 h, strongly suggesting that at least one
additional pathway of MMP-9 activation exists. This unidenti-
fied pathway of activation likely contributes to both the early
and late stages of experimental BP pathogenesis, because mice
lacking both mMCP-4 and plasmin activity exhibit MMP-9
activationwithin 4 hof antibody injection and increased disease
severity over the course of 48 h.Wehypothesize that infiltrating
PMN-released MMP-9 is initially activated by both a plasmin-
dependent mechanism and unidentified other activators, fol-
lowed by mMCP-4. Further investigation is needed to identify
the functional interplay between plasmin- and mMCP-4-de-
pendent pathways forMMP-9 activation in experimental BP, as
well as unidentified plasmin- and mMCP-4-independent
pathways.
The discovery of the dual targets of mMCP-4 further eluci-
dates a complex net of interactions that control local inflamma-
tion and tissue injury in experimental BP (Fig. 8). Because
mMCP-4 is the functional homolog of human chymase, our
current findings give us new insights into the immunopatho-
genesis of human autoimmune diseases and implicate this chy-
mase as a promising potential therapeutic target in human
disease.
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